1-ヒドラジノフタラジン

1-ヒドラジノフタラジン 化学構造式
86-54-4
CAS番号.
86-54-4
化学名:
1-ヒドラジノフタラジン
别名:
アプレソリン;アプレゾリン;アプレッシン;(フタラジン-1-イル)ヒドラジン;ヒドララジン;1-(フタラジン-1-イル)ヒドラジン;フタラジン-1(2H)-オンヒドラゾン;1-ヒドラジノフタラジン;1-ヒドラジニルフタラジン
英語名:
Hydralazine
英語别名:
c5968;ba5968;c-5068;apressin;ciba5968;apresolin;aprezolin;NSC 126699;apresoline;hidralazin
CBNumber:
CB1855362
化学式:
C8H8N4
分子量:
160.18
MOL File:
86-54-4.mol
MSDS File:
SDS

1-ヒドラジノフタラジン 物理性質

融点 :
172°C
沸点 :
276.07°C (rough estimate)
比重(密度) :
1.2583 (rough estimate)
屈折率 :
1.5872 (estimate)
酸解離定数(Pka):
pKa 6.820± 0.005(H2O,t = 25.0,Iundefined) (Uncertain)
水溶解度 :
4.8mg/L(22.5℃)
BCS Class:
3
CAS データベース:
86-54-4
IARC:
3 (Vol. 24, Sup 7) 1987
NISTの化学物質情報:
1(2H)-phthalazinone, hydrazone(86-54-4)
EPAの化学物質情報:
Hydralazine (86-54-4)
安全性情報
  • リスクと安全性に関する声明
  • 危険有害性情報のコード(GHS)
毒性 LD50 in mice, rats (mg/kg): 122, 90 orally; 101, 40 i.p. (Dorigotti)
絵表示(GHS) GHS hazard pictograms
注意喚起語 危険
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード
H301 飲み込むと有毒 急性毒性、経口 3 危険 GHS hazard pictograms P264, P270, P301+P310, P321, P330,P405, P501
注意書き
P264 取扱い後は皮膚をよく洗うこと。
P264 取扱い後は手や顔をよく洗うこと。
P270 この製品を使用する時に、飲食または喫煙をしないこ と。
P405 施錠して保管すること。
P501 内容物/容器を...に廃棄すること。

1-ヒドラジノフタラジン 価格

メーカー 製品番号 製品説明 CAS番号 包装 価格 更新時間 購入

1-ヒドラジノフタラジン MSDS


Hydralazine

1-ヒドラジノフタラジン 化学特性,用途語,生産方法

用途

血管拡張薬 降圧薬

効能

血圧降下薬, 血管拡張薬

説明

Cross-reactions between hydrazine derivatives occur. Hydralazine may sometimes cause flushing and reversible Lupus erythematosis

化学的特性

Yiellow Solid

使用

Hydralazine is a non-nucleoside analog that inhibits DNA methylation and reactivates the expression of tumor suppressor genes. Non-selective MAO-A/B inhibitor; semicarbazide-sensitive amine oxidase inhibitor. Antihypertensive.

定義

ChEBI: The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.

生物学の機能

The vasodilation produced by hydralazine (Apresoline) depends in part on the presence of an intact blood vessel endothelium. This implies that hydralazine causes the release of nitric oxide, which acts on the vascular smooth muscle to cause relaxation. In addition, hydralazine may produce vasodilation by activating K+ channels.

接触アレルゲン

Hydralazine is a hydrazine derivative used as a antihypertensive drug. Skin rashes have been described during treatment. Exposure occurs mainly in the pharmaceutical industry. Cross-sensitivity is frequent with hydrazine, which is considered to be a potent sensitizer.

作用機序

Hydralazine exhibits an antihypertensive effect by directly relaxing smooth muscles of the vessels. It has an effect on arterial vessels while having a minimal effect on venous vessels. As a result, resistance of peripheral vessels decreases, and blood pressure is reduced (diastolic more than systolic).
It does not have a substantial effect on nonvascular smooth musculature or cardiac tissues. Homeostatic circulatory reflexes remain natural, and the resulting hypotension activates cardiovascular reflexes, which are expressed as an increase of heart work, power, and volume of cardiac output. Therefore, it is most effectively used in combination with β-blockers.

薬理学

Hydralazine produces widespread but apparently not uniform vasodilation; that is, vascular resistance is decreased more in cerebral, coronary, renal, and splanchnic beds than in skeletal muscle and skin. Renal blood flow and ultimately glomerular filtration rate may be slightly increased after acute treatment with hydralazine. However, after several days of therapy, the renal blood flow is usually no different from that before drug use.
In therapeutic doses, hydralazine produces little effect on nonvascular smooth muscle or on the heart. Its pharmacological actions are largely confined to vascular smooth muscle and occur predominantly on the arterial side of the circulation; venous capacitance is much less affected. Because cardiovascular reflexes and venous capacitance are not affected by hydralazine, postural hypotension is not a clinical concern. Hydralazine treatment does, however, result in an increase in cardiac output.This action is brought about by the combined effects of a reflex increase in sympathetic stimulation of the heart, an increase in plasma renin, and salt and water retention. These effects limit the hypotensive usefulness of hydralazine to such an extent that it is rarely used alone.

臨床応用

Hydralazine is generally reserved for moderately hypertensive ambulatory patients whose blood pressure is not well controlled either by diuretics or by drugs that interfere with the sympathetic nervous system. It is almost always administered in combination with a diuretic (to prevent Na+ retention) and a β-blocker, such as propranolol (to attenuate the effects of reflex cardiac stimulation and hyperreninemia). The triple combination of a diuretic, β-blocker, and hydralazine constitutes a unique hemodynamic approach to the treatment of hypertension, since three of the chief determinants of blood pressure are affected: cardiac output (β-blocker),plasma volume (diuretic), and peripheral vascular resistance (hydralazine).
Although hydralazine is available for intravenous administration and has been used in the past for hypertensive emergencies, it is not generally employed for this purpose. The onset of action after intravenous injection is relatively slow, and its actions are somewhat unpredictable in comparison with those of several other vasodilators.

副作用

Most side effects associated with hydralazine administration are due to vasodilation and the reflex hemodynamic changes that occur in response to vasodilation. These side effects include headache, flushing, nasal congestion, tachycardia, and palpitations. More serious manifestations include myocardial ischemia and heart failure. These untoward effects of hydralazine are greatly attenuated when the drug is administered in conjunction with a β-blocker.
When administered chronically in high doses, hydralazine may produce a rheumatoidlike state that when fully developed, resembles disseminated lupus erythematosus.

純化方法

It crystallises from MeOH. UV: max 656nm at pH ~11. It complexes with Bi3+ , Zn2+ , Fe2+ and Co2+ .

1-ヒドラジノフタラジン 上流と下流の製品情報

原材料

準備製品


1-ヒドラジノフタラジン 生産企業

Global( 69)Suppliers
名前 電話番号 電子メール 国籍 製品カタログ 優位度
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21691 55
Hubei Jusheng Technology Co.,Ltd.
18871490254
linda@hubeijusheng.com CHINA 28180 58
Standardpharm Co. Ltd.
86-714-3992388
overseasales1@yongstandards.com United States 14336 58
Antai Fine Chemical Technology Co.,Limited
18503026267
info@antaichem.com CHINA 9641 58
TargetMol Chemicals Inc.
+1-781-999-5354 +1-00000000000
marketing@targetmol.com United States 19892 58
Career Henan Chemica Co
+86-0371-86658258 15093356674;
laboratory@coreychem.com China 30255 58
Xi'an MC Biotech, Co., Ltd.
029-89275612 +8618991951683
mcbio_sales@163.com China 2255 58
Shaanxi Dideu Medichem Co. Ltd
+86-029-89586680 +86-18192503167
1026@dideu.com China 9320 58
Dideu Industries Group Limited
+86-29-89586680 +86-15129568250
1026@dideu.com China 29220 58
AFINE CHEMICALS LIMITED
0571-85134551
info@afinechem.com CHINA 15377 58

86-54-4(1-ヒドラジノフタラジン)キーワード:


  • 86-54-4
  • hydralazine
  • apresoline
  • 1(2h)-phthalazinonehydrazone
  • 1-Phthalazinylhydrazine
  • Hydralazine Discontinued See: H716531
  • NSC 126699
  • Phthalazine,1-hydrazinyl-
  • 1-hydrazino-phthalazin
  • 1-hydrazinophthalazine
  • apresolin
  • apressin
  • aprezolin
  • ba5968
  • c-5068
  • c5968
  • ciba5968
  • hidralazin
  • hidralazina
  • hipoftalin
  • hydralazin
  • hydrallazine
  • hydrazinophthalazine
  • hypophthalin
  • phthalazin-1-ylhydrazine
  • 1-Hydrazinylphthalazine
  • 1-HydrazinophthalazineDiscontinued See: H716531
  • Dihydralazine Impurity 2
  • Dihydralazine Impurity 2(Dihydralazine EP Impurity B)
  • Dihydralazine EP Impurity B
  • Penehyclidine Impurity 7
  • アプレソリン
  • アプレゾリン
  • アプレッシン
  • (フタラジン-1-イル)ヒドラジン
  • ヒドララジン
  • 1-(フタラジン-1-イル)ヒドラジン
  • フタラジン-1(2H)-オンヒドラゾン
  • 1-ヒドラジノフタラジン
  • 1-ヒドラジニルフタラジン
  • 降圧薬
  • 血管拡張薬
Copyright 2017 © ChemicalBook. All rights reserved